Servier Expands Oncology Footprint

Servier India has received approval for Vorasidenib (Voranigo), adding a second rare-cancer treatment to its portfolio in the country. The targeted IDH inhibitor offers an option for patients with Grade 2 IDH-mutant glioma, a brain tumour that affects younger adults and has had limited therapeutic developments. With its earlier launch of Tibsovo® for IDH1-mutated AML and cholangiocarcinoma, Servier says its strategy in India focuses on science-led development, unmet clinical needs and widening access to approved oncology therapies.